G. Lelais

Materials Science · Physical Sciences

16h-index2.7kcitations75works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Crystallization and Solubility Studies(32), X-ray Diffraction in Crystallography(32), Lung Cancer Treatments and Mutations(17), Chemical Synthesis and Analysis(15), Crystallography and molecular interactions(11)

Publications75 total

Abstract 3022: ODY-CDK, a brain-penetrant, selective CDK2 inhibitor that demonstrates antitumor activity in an intracranial <i>CCNE1</i>-amplified breast tumor model
Cancer Research·2025· 1 cited
Data from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Table 1 from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Data from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Figure Legends from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Figures 1 through 5 from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Table 1 from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Material and Methods from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Material and Methods from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Figures 1 through 5 from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Supplementary Figure Legends from EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
2023Open Access
Structure-Based Design of Selective LONP1 Inhibitors for Probing <i>In Vitro</i> Biology
Journal of Medicinal Chemistry·2021· 17 citedOpen Access
Dexamethasone inhibits respiratory syncytial virus-driven mucus production while increasing viral replication without altering antiviral interferon signaling
Virology·2019· 16 cited
Development of a virtual reality platform for effective communication of structural data in drug discovery
Journal of Molecular Graphics and Modelling·2019· 71 citedOpen Access
Integrating pharmacokinetic-pharmacodynamic modeling in preclinical assessment of mutant selective EGFR covalent tyrosine kinase inhibitor EGF816
Drug Metabolism and Pharmacokinetics·2019
Discovery of (<i>R</i>,<i>E</i>)-<i>N</i>-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers
Journal of Medicinal Chemistry·2016· 94 citedOpen Access
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Nature·2016· 851 citedOpen Access
EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
Cancer Research·2016· 120 citedOpen Access
EGF816, an irreversible mutant-selective EGFR inhibitor, is effective in NSCLC with both primary activating and T790M-mediated resistant EGFR mutations
2016
Abstract 2585: Discovery of a potent covalent mutant-selective EGFR inhibitor - the journey from high throughput screening to EGF816
Cancer Research·2015· 1 cited
page 1 of 4Next →

Frequent Co-authors

Dieter Seebàch(26), P. Micuch(18), Laurent Schaeffer(16), F. Gessier(16), P. Bindschädler(16), D. Josien(16), Radovan Šebesta(16), W. Bernd Schweizer(16), Y.R. Mahajan(15), C. Jager(14), Pierre‐Yves Michellys(10), Robert Epple(10), Matthew McNeill(10), S. Kopp(9), Yong Jia(8), Mari Manuia(8), Michael DiDonato(8), Badry Bursulaya(8), Thomas H. Marsilje(8), Shailaja Kasibhatla(8)